Neurocrine Biosciences (NBIX) Short-term Investments (2010 - 2026)

Neurocrine Biosciences' Short-term Investments history runs 17 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• Quarterly Short-term Investments rose 40.07% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 40.07% YoY) and the FY2025 annual result came in at $767.4 million, down 8.98% from the prior year.
• Short-term Investments was $1.0 billion for Q1 2026 at Neurocrine Biosciences, up from $767.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $1.0 billion in Q1 2026 and bottomed at $394.7 million in Q1 2022.
• A 5-year average of $757.1 million and a median of $780.5 million in 2023 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments slipped 24.26% — and 2023, when it surged 100.35%.
• Neurocrine Biosciences' Short-term Investments stood at $726.4 million in 2022, then grew by 7.45% to $780.5 million in 2023, then rose by 8.02% to $843.1 million in 2024, then fell by 8.98% to $767.4 million in 2025, then soared by 36.79% to $1.0 billion in 2026.
• Business Quant data shows NBIX's Short-term Investments at $1.0 billion in Q1 2026, $767.4 million in Q4 2025, and $774.6 million in Q3 2025.